| Business Summary | | Interleukin
Genetics,
Inc.
is
a
functional
genomics
company
focused
on
personalized
medicine.
The
Company
has
a
portfolio
of
patents
covering
the
genetics
of
many
common
diseases
and
conditions,
including
cardiovascular
diseases,
osteoporosis,
complications
of
diabetes,
restenosis
and
periodontal
disease.
Its
first
genetic
test,
PST,
a
test
predictive
of
risk
for
periodontal
disease,
is
currently
marketed
in
the
United
States,
Europe
and
Israel.
Other
products
under
development
include
tests
predictive
of
risk
for
osteoporosis,
coronary
artery
disease,
complications
of
diabetes
and
restenosis.
The
Company
has
also
developed
and
licensed
medical
research
tools,
including
BioFusion,
to
pharmaceutical
and
biotech
companies.
BioFusion
is
a
computer
modeling
system
that
allows
useful
information
to
be
derived
from
rapidly
increasing
databases
of
gene
expression
being
generated
in
companies
and
academic
centers
worldwide. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Interleukin
Genetics,
Inc.
provides
genetic
susceptibility
testing
services
for
common
and
treatable
diseases.
The
Company
focuses
on
four
diseases;
periodontitis,
osteoporosis,
coronary
artery
and
diabetic
retinopathy.
For
the
six
months
ended
6/30/01,
revenues
fell
5%
to
$159
thousand.
Net
loss
decreased
10%
to
$2.3
million.
Revenues
reflect
a
change
in
strategy
for
marketing,
distributing
and
processing
PST.
Lower
loss
benefitted
from
decreased
administrative
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Philip Reilly, M.D., 53 Chairman
and CEO | $307K | $74K | Kenneth Kornman, Ph.D., 53 Pres,
CSO | 368K | -- | Fenel Eloi, 42 COO,
Chief Financial Officer | 106K | -- | Paul Martha, Jr., M.D., 47 CMO | 23K | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|